Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 1320Neoplasms 1100Carcinoma, Non-Small-Cell Lung 911Prostatic Neoplasms 741Colorectal Neoplasms 648Lung Neoplasms 611Neoplasm Metastasis 469Multiple Myeloma 444Leukemia, Myeloid, Acute 428Pancreatic Neoplasms 388Ovarian Neoplasms 387Melanoma 342Carcinoma, Hepatocellular 308Recurrence 289Brain Neoplasms 286Squamous Cell Carcinoma of Head and Neck 284Glioblastoma 259Head and Neck Neoplasms 253Stomach Neoplasms 251Precursor Cell Lymphoblastic Leukemia-Lymphoma 240Carcinoma, Renal Cell 237Triple Negative Breast Neoplasms 233Lymphoma 232Endometrial Neoplasms 221Hematologic Neoplasms 214Uterine Cervical Neoplasms 212Urinary Bladder Neoplasms 210Lymphoma, Non-Hodgkin 205Glioma 202Sarcoma 201

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Atypical Hemolytic Uremic Syndrome × 90 days × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔